临界性肺动脉高压的预后效应与纵向血流动力学评估
该回顾性队列研究纳入1998至2014年在范德堡大学医学中心接受右心导管检查的4343例患者,按平均肺动脉压(mPAP)分为参考组(≤18 mm Hg)、临界性肺动脉高压组(19–24 mm Hg)和肺动脉高压组(≥25 mm Hg)。结果显示临界性肺动脉高压与死亡率增加独立相关(HR 1.31;95% CI 1.04–1.65;在70例重复导管检查的临界性肺动脉高压患者中,43例(61%)进展为显性肺动脉高压。
要点
- 临界性肺动脉高压(mPAP 19–24 mm Hg)与全因死亡率独立增加相关(HR 1.31)。
- mPAP升高与死亡风险呈连续递增关系,未观察到明确阈值。
- 临界性肺动脉高压患者中61%在重复导管时进展为显性肺动脉高压。
核心结论
- 临界性肺动脉高压在接受右心导管检查的患者中常见,与显著合并症、进展为显性肺动脉高压及生存率下降相关。
- mPAP的小幅升高(即使在目前认为正常的范围内)与死亡率增加独立相关。
研究设计与样本
- 回顾性队列研究,1998至2014年单中心(范德堡大学医学中心)接受常规右心导管检查的4343例患者。
- 按mPAP分为参考组(≤18 mm Hg)、临界性肺动脉高压组(19–24 mm Hg)和肺动脉高压组(≥25 mm Hg)。
- 主要结局为全因死亡率(Cox比例风险模型调整34个协变量),次要结局为临界性肺动脉高压患者进展为显性肺动脉高压。
主要发现
- 肺动脉高压和临界性肺动脉高压的患病率分别为62%和18%。
- 死亡风险随mPAP升高呈连续递增,未观察到阈值。
- 高龄、代谢综合征特征及慢性心肺疾病与临界性肺动脉高压可能性更高独立相关。
关键数值与推荐
- 临界性肺动脉高压定义为mPAP 19–24 mm Hg,参考组为mPAP≤18 mm Hg,肺动脉高压为mPAP≥25 mm Hg。
临床怎么用
- 对于右心导管检查发现mPAP处于19–24 mm Hg的患者,应认识到其死亡风险增加及可能进展为显性肺动脉高压。
- 对此类患者可考虑更密切的监测,但早期干预能否改善临床结局尚需前瞻性研究确定。
局限性
- 研究为单中心回顾性队列设计。
- 重复右心导管检查的临界性肺动脉高压患者样本量较小(70例)。
- 早期干预或更密切监测能否改善临床结局尚待前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Pulmonary hypertension (PH) is diagnosed by a mean pulmonary arterial pressure (mPAP) value of at least 25 mm Hg during right heart catheterization (RHC). While several studies have demonstrated increased mortality in patients with mPAP less than that threshold, little is known about the natural history of borderline PH. OBJECTIVE: To test the hypothesis that patients with borderline PH have decreased survival compared with patients with lower mPAP and frequently develop overt PH and to identify clinical correlates of borderline PH. DESIGN, SETTING, AND PARTICIPANTS: Retrospective cohort study from 1998 to 2014 at Vanderbilt University Medical Center, comprising all patients undergoing routine RHC for clinical indication. We extracted demographics, clinical data, invasive hemodynamics, echocardiography, and vital status for all patients. Patients with mPAP values of 18 mm Hg or less, 19 to 24 mm Hg, and at least 25 mm Hg were classified as reference, borderline PH, and PH, respectively. EXPOSURES: Mean pulmonary arterial pressure. MAIN OUTCOME AND MEASURES: Our primary outcome was all-cause mortality after adjusting for clinically relevant covariates in a Cox proportional hazards model. Our secondary outcome was the diagnosis of overt PH in patients initially diagnosed with borderline PH. Both outcomes were determined prior to data analysis. RESULTS: We identified 4343 patients (mean [SD] age, 59 [15] years, 51% women, and 86% white) among whom the prevalence of PH and borderline PH was 62% and 18%, respectively. Advanced age, features of the metabolic syndrome, and chronic heart and lung disease were independently associated with a higher likelihood of borderline PH compared with reference patients in a logistic regression model. After adjusting for 34 covariates in a Cox proportional hazards model, borderline PH was associated with increased mortality compared with reference patients (hazard ratio, 1.31; 95% CI, 1.04-1.65; P = .001). The hazard of death increased incrementally with higher mPAP, without an observed threshold. In the 70 patients with borderline PH who underwent a repeated RHC, 43 (61%) had developed overt PH, with a median increase in mPAP of 5 mm Hg (interquartile range, -1 to 11 mm Hg; P < .001). CONCLUSIONS AND RELEVANCE: Borderline PH is common in patients undergoing RHC and is associated with significant comorbidities, progression to overt PH, and decreased survival. Small increases in mPAP, even at values currently considered normal, are independently associated with increased mortality. Prospective studies are warranted to determine whether early intervention or closer monitoring improves clinical outcomes in these patients.
引用
- Assad TR, Maron BA, Robbins IM, et al. Prognostic Effect and Longitudinal Hemodynamic Assessment of Borderline Pulmonary Hypertension. JAMA Cardiol. 2017. PMID: 29071338. doi:10.1001/jamacardio.2017.3882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。